CDKN1A Gene Expression in Two Multiple Myeloma Cell Lines With Different P53 Functionality

Autor:	Zdenek Kolar, Denisa Hrckova Drozdkova, Jiri Minarik, Katerina Smesny Trtkova, Ivo Uberall, Jan Gursky
Rok vydání:	2020
Předmět:	Cancer Research Kinase Chemistry General Medicine CDKN1A Gene medicine.disease Anticancer drug Oncology Cell culture Apoptosis Gene expression Cancer research medicine Histone deacetylase Multiple myeloma
Zdroj:	Anticancer Research. 40:4979-4987
ISSN:	1791-7530 0250-7005
DOI:	10.21873/anticanres.14501
Popis:	Background/aim Multiple myeloma is a highly heterogeneous disease of clonal plasma cells. Histone deacetylase (HDAC) inhibitors are promising anticancer drugs but their precise mechanisms of actions are not well understood. Materials and methods Cell-cycle regulation and pro-apoptotic effects of two histone deacetylase inhibitors, suberohydroxamic acid (SAHA) and suberoylanilide hydroxamic acid (SBHA), were analyzed in multiple myeloma cell lines RPMI8226 and U266 with differing TP53 status using gene-expression analysis. Results Enhanced expression of cyclin-dependent kinase inhibitor 1A (CDKN1A/p21WAF/CIP1) detected in the TP53-deleted U266 cell line after SAHA treatment indicates the P53-independent mode of transcriptional activation of CDKN1A gene. In contrast, CDKN1A gene expression was significantly increased by both SBHA and SAHA treatment of TP53-mutated RPMI8226 cells. Conclusion SAHA appears to be a potentially effective pro-apoptotic and anticancer drug with universal application in the treatment of heterogeneous populations of multiple myeloma cells.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::6eb3272f3b9ec4824eb07db2a2babe86 https://doi.org/10.21873/anticanres.14501 Zobrazit plný text záznamu